Floatz logo

Vorinostat

Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma

AIDS Malignancy ConsortiumSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Cetuximab
National Cancer Institute (NCI)
Phase 1/2B
Irinotecan
AIDS Malignancy Consortium
Phase 1/2B
Carboplatin
Rapa Therapeutics LLC
Phase 1/2B
AUTOLOGOUS RAPAMYCIN-RESISTANT TH1/TC1 CELLS RAPA-201
Rapa Therapeutics LLC
Phase 1/2CCC
Pembrolizumab
Rapa Therapeutics LLC
Phase 1/2CCC

View all 15 →

Same molecule, other indications

Vorinostat is also rated in:

Non-Small-Cell Lung CarcinomaDormant
BB
Indicative ·
71 / 100
View asset →
Hodgkins lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
Recurrent Non-Hodgkin LymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →